

## BY HAND

Joinn Laboratories (China) Co., Ltd. A5 Rongjing East Street Beijing Economic-Technological Development Area Beijing, 100176, China

浤博資本有限公司 Rainbow Capital (HK) Limited

香港上環禧利街 2 號 東寧大廈 12 樓 5B 室 Room 5B, 12/F Tung Ning Building No. 2 Hillier Street Sheung Wan, Hong Kong

31 October 2022

Dear Sirs,

Re:

Joinn Laboratories (China) Co., Ltd. (the "Company") -

Connected transaction – issue and grant of restricted shares by the Company to the connected participants under the incentive scheme (the "Transaction")

We refer to the circular of the Company dated 31 October 2022 (the "Circular") in connection with the Transaction. Capitalised terms used in this letter shall have the same meaning as those defined in the Circular unless otherwise specified.

We hereby give our consent, and confirm that we have not withdrawn our consent to the issue of the Circular with the inclusion of our letter or opinion addressed to the Independent Board Committee and the Independent Shareholders (the "IFA Letter") and references to our name and opinion in the form and context in which they appear.

We also confirm that as at the Latest Practicable Date, we (i) did not have any direct or indirect interest in any assets acquired or disposed of by or leased to, or proposed to be acquired or disposed of by or leased to any member of the Group since 31 December 2021, being the date to which the latest published audited consolidated financial statements of the Group were made up; and (b) did not have any shareholding in any member of the Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group.

We hereby consent to this letter and the IFA Letter being made available for public inspection as described in the Circular.

Yours faithfully, For and on behalf of Rainbow Capital (HK) Limited

Name: Danny Leung
Title: Managing Director